Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study

Journal of Medical Economics

Volumn 20, Issue 1, 2017, Pages 28-36

  Punekar, Yogesh Suresh ^a   Naya, Ian ^a   Small, Mark ^b   Holbrook, Tim ^b   Wood, Robert ^b   Mullerova, Hana ^a   Valle, Manuel ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ADELPHI REAL WORLD   (United Kingdom)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

COPD; Costs; Dyspnea; Reliever use; Resource use

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; SHORT ACTING DRUG; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DYSPNEA; FEMALE; GLOBAL DISEASE BURDEN; HEALTH CARE UTILIZATION; HEALTH STATUS; HOSPITALIZATION COST; HUMAN; INHALER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MIDDLE AGED; SLEEP QUALITY; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; HEALTH CARE COST; METERED DOSE INHALER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; UTILIZATION;

AGED; BRONCHODILATOR AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84983759429     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.1080/13696998.2016.1223085     Document Type: Article

References (50)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. http://goldcopd.org/guidelines/guidelines-resources.html. Last accessed January 13, 2016
2. WHO. World Health Report. 2000. Geneva:World Health Organisation. http://www.who.int/whr/2000/en/. Last accessed January 13, 2016
3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
4. Punekar YS, Shukla A, Mullerova H., COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis 2014;9:65-73
5. van Schayck CP, Folgering H, Harbers H, et al. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 1991;46:355-9
6. van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-85
7. Kerstjens HA, Bantje TA, Luursema PB, et al. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest 2007;132:1493-9
8. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015. http://www.ginasthma.org/GINA Committee. Last accessed January 13, 2016
9. Jones PW, Donohue JF, Nedelman J, et al. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease:a pooled analysis. Respir Res 2011;12:161
10. Calverley P, Pauwels DR, Lofdahl CG, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J 2005;26:406-13
11. Han M, Vieira MC, Cope S, et al. The association between reliever medication use and future exacerbations in COPD:A retrospective analysis of randomized controlled trials. Chest 2012;142:696A
12. Edwards SC, Fairbrother SE, Scowcroft A, et al. Current COPD disease burden associated with maintenance monotherapy in the UK. Thorax 2014;69(Suppl 2):A186
13. Corrao G1, Zambon A, Faini S, et al. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol 2005;58:92-7
14. Anderson P., Benford M, Harris N, et al. Real-world physician and patient behavior across countries:Disease-specific programmes–a means to understand. Curr Med Res Opin 2008;24:3063-72
15. Punekar YS, Mullerova H, Small M, et al. Prevalence and burden of dyspnea among COPD patients in five European countries. Pulm Ther 2016;2:59
16. Charlson ME, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies:Development and validation. J Chron Dis 1987;40:373-83
17. Bestall J, Paul E, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6
18. Jones P, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J 2009;34:648-54
19. EuroQoL Group. EuroQoL—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
20. Jenkins DC, Stanton B, Niemcryk SJ, et al. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988;41:313-21
21. Morisky DE, Green LW, Levine DM., Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74
22. European Society for Opinion and Marketing Research (ESOMAR). International code of marketing and social research practice; 2007. http://ethics.iit.edu/ecodes/node/5178. Last access January 13, 2016
23. Menn P, Heinrich J, Huber RM, et al. Direct medical costs of COPD—an excess cost approach based on two population-based studies. Respir Med 2012;106:540-8
24. Fédération Hospitalière de France. GACAH 2009. 2009. http://www.fhf.fr/Actualites/Finances-BDHF/comptabilite-analytique/GACAH-2009. Last access January 13, 2016
25. Ministero della Salute. Proposta metodologica per la valutazione dei costi dell’emergenza. 2007. http://www.mattoni.salute.gov.it/mattoni/documenti/11_Valutazione_costi_dell_emergenza.pdf. Last access January 13, 2016
26. Department of Health. NHS reference costs:financial year 2011 to 2012. 2012. https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012. Last access January 13, 2016
27. Échantillon Généraliste de Bénéficiaires. 2014. http://www.iresp.net/iresp/files/2013/04/091020182511_pos093_echantillon_g.pdf. Accessed Jan 13, 2016.
28. Freytag A, Storz P, Hagenmeyer EG, et al. Direct cost of treatment of COPD in a German sickness fund. iHEA 6th World Congress, July 8–11, 2007, Copenhagen
29. SDO. Rapporto annuale sull’attività di ricovero ospedaliero dati 2010. 2010. http://www.salute.gov.it/imgs/C_17_pubblicazioni_1690_allegato.pdf. Last accessed January 13, 2016
30. Garattini L, Castelnuovo E, Lanzeni D, et al. Durata e costo delle visite in medicina generale:il progetto DYSCO. Farmeconomia e percorsi terapeutici 2003;4:109-14
31. PSSRU. Unit costs of health and social care 2012. 2012. http://www.pssru.ac.uk/project-pages/unit-costs/2012/. Last accessed January 13, 2016
32. Agenzia Nazionale per i Servizi Sanitari Regionali. Tariffe delle prestazioni specialistiche ambulatoriali aggiornato al 31 dicembre 2009. 2009. http://www.agenas.it/monitoraggio_costi_tariffe/2009_SPECIALISTICA_ex%20DM%2096per%20sito.pdf. Last accessed January 13, 2016
33. Murgia A, Scano G, Palange P, et al. Guidelines for long-term oxygen therapy. Update 2004. Rassegna Di Patologia Dell’Apparato Repiratorio 2004;19:206-19
34. Tarricone R, Lazzaro C., Valutazione degil aspetti economico-sanitari dell’ossigenoterapia domiciliare. 2003. http://www.gco.it/Valutazione%20degli%20aspetti%20economico%20sanitari%20OTD.pdf. Last accessed January 13, 2016
35. Lucioni DC, Donner CF, De Benedetto F, et al. I costi della broncopneumopatia cronica ostruttiva in Italia. Presentazione della prima fase dello studio ICE (Italian Costs for Exacerbations in COPD). Pharmacoeconomics 2005;7:119-34
36. Department of Health. Consultation on a strategy for devices for chronic obstructive pulmonary disease (COPD) in England. 2010. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213840/dh_113279.pdf. Last accessed January 13, 2016
37. Austin PC., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
38. Abadie A, Imbens G., Large sample properties of matching estimators for average treatment effects. Econometrica 2006;74:235-67
39. Abadie A, Imbens G., Bias-corrected matching estimators for average treatment effects. J Bus Econ Stat 2011;29:1.
40. Abadie A, Imbens G., On the failure of the bootstrap for matching estimators. Econometrica 2008;76:1537-58
41. Abadie A, Imbens G., Matching on the estimated propensity score. 2012 National Bureau of Economic Research Working Paper No. 15301. http://www.hks.harvard.edu/fs/aabadie/pscore.pdf. Last accessed January 13, 2016
42. Rosenbaum P.R., Observational studies. Springer Series in Statistics. Springer; 2002. pp 1-17
43. Partridge MR, Karlsson N, Small IR., Patient insight into the impact of chronic obstructive pulmonary disease in the morning:an internet survey. Curr Med Res Opin 2009;25:2043-8
44. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD:a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
45. Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control:the relationship between current control and future risk. J Allergy Clin Immunol 2010;125:600-8
46. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65
47. Eisner MD, Lieu TA, Chi F, et al. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001;17:233-40
48. Senthilselvan A, Lawson JA, Rennie DC, et al. Regular use of corticosteroids and low use of short-acting beta2-agonists can reduce asthma hospitalization. Chest 2005;127:1242-51
49. Jenkins CR, Postma DS, Anzueto AR, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med 2015;15:97
50. Stenton C., The MMRC dyspnea scale. Occup Med 2008;58:226-7